Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc.TARS · Entity 1836 | Director · President/CEO and Board Chair | September 04, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tarsus Pharmaceuticals, Inc.
Report date September 04, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy the Bobak Azamian Living Trust established April 16, 2018 | 827,991 |
Last balance in matching sequence
After 2026-09-04 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-09-04 · Sale · Disposed 7,100 · Balance 830,891 F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025. F2: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $90.00 to $90.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Row 2 · 2026-09-04 · Sale · Disposed 2,900 · Balance 827,991 F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025. F4: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $91.06 to $91.45. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. |
| Common StockSEC Table I · non-derivative | Direct | 33,421 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 33,421 |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025.
F2: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $90.00 to $90.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.
F4: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $91.06 to $91.45. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2021 Filed Nov 3, 2021 22:55 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 800 | $28.21 | $22,568.00 |
DisclosureSEC source: 0001819790-21-000041 · wf-form4_163598012144660.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,209,939 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021. F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $28.10 to $28.27. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 22:55 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 5,033 | $27.76 | $139,716.08 |
DisclosureSEC source: 0001819790-21-000041 · wf-form4_163598012144660.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,210,739 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $27.10 to $28.09. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| October 12, 2021 Filed Oct 14, 2021 20:44 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 4,698 | $26.44 | $124,215.12 |
DisclosureSEC source: 0001819790-21-000037 · wf-form4_163424427780477.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,215,772 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021. F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $26.05 to $26.76. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| October 12, 2021 Filed Oct 14, 2021 20:44 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 833 | $25.49 | $21,233.17 |
DisclosureSEC source: 0001819790-21-000037 · wf-form4_163424427780477.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,220,470 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $25.04 to $26.00. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 22:43 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 302 | $25.02 | $7,555.44 |
DisclosureSEC source: 0001819790-21-000033 · wf-form4_163407859702568.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,221,303 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $25.000 to $25.055. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:51 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 100 | $26.40 | $2,640.00 |
DisclosureSEC source: 0001827672-21-000002 · wf-form4_163070587277035.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,221,605 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:51 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 5,733 | $25.23 | $144,660.79 |
DisclosureSEC source: 0001827672-21-000002 · wf-form4_163070587277035.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,221,705 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $25.000 to $25.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| August 11, 2021 Filed Aug 12, 2021 21:26 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 1,917 | $25.07 | $48,061.11 |
DisclosureSEC source: 0001209191-21-051191 · doc4.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,227,438 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021. F3 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $25.000 to $25.275. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 21:26 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 103 | $25.00 | $2,575.00 |
DisclosureSEC source: 0001209191-21-051191 · doc4.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,229,355 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021. F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 20:53 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 100 | $25.13 | $2,513.00 |
DisclosureSEC source: 0001209191-21-050626 · doc4.xml · nonDerivative · entry 3 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,229,458 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021. F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 20:53 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 727 | $25.00 | $18,175.00 |
DisclosureSEC source: 0001209191-21-050626 · doc4.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,229,558 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021. F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 20:53 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 1,616 | $25.00 | $40,400.00 |
DisclosureSEC source: 0001209191-21-050626 · doc4.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,230,285 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021. F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 20:14 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 1,370 | $25.00 | $34,250.00 |
DisclosureSEC source: 0001209191-21-050176 · doc4.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,231,901 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021. F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 21:53 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 204,998 | $0.00 Strike: $47.25 | $0.00 |
DisclosureSEC source: 0001209191-21-002738 · doc4.xml · derivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,998 Underlying: Common Stock · 204,998 shares Expires 2031-01-06 F1 · derivative.exercise_date: 25% of the option shares shall vest on January 7, 2022, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 23:53 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | ConversionSeries B Preferred Stock · Derivative | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055419 · doc4.xml · derivative · entry 4 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 23:53 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | ConversionSeries A Preferred Stock · Derivative | 21,575 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055419 · doc4.xml · derivative · entry 3 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 0 Underlying: Common Stock · 21,575 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 23:53 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | ConversionCommon Stock | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055419 · doc4.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 23:53 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | ConversionCommon Stock | 21,575 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055419 · doc4.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,233,271 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.